HRAS and head and neck squamous cell carcinoma: Currently a Phase II clinical trial is recruiting patients to assess the safety and efficacy of tipifarnib in HNSCC with HRAS mutations and impact of HRAS on response to therapy (AIM-HN/SEQ-HN) (NCT03719690).